Management of the irritable bowel syndrome

Gastroenterology

Volumn 120, Issue 3, 2001, Pages 652-668

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; AMITRIPTYLINE; DESIPRAMINE; DIPHENOXYLATE; LACTULOSE; LOPERAMIDE; MACROGOL; MAGNESIUM SALT;

ALGORITHM; CLINICAL FEATURE; COST OF ILLNESS; DIAGNOSTIC APPROACH ROUTE; HUMAN; IRRITABLE COLON; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; TREATMENT OUTCOME;

EID: 0035109696     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.21908     Document Type: Article

References (176)

1. Rome II: A multinational consensus document on functional gastrointestinal disorders
2. A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease
3. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome
4. Towards a positive diagnosis of the irritable bowel
5. Irritable bowel syndrome: Guidelines for the diagnosis
6. Functional bowel disorders and functional abdominal pain
7. The irritable bowel syndrome: Mechanisms and a practical approach to management
8. Irritable bowel syndrome: A technical review for practice guideline development
9. Review article: Irritable bowel syndrome
10. U.S. householder survey of functional gastrointestinal disorders
11. Irritable bowel syndrome in a community: Symptom subgroups, risk factors and health care utilization
12. The effect of new diagnostic criteria for irritable bowel syndrome on community prevalence estimates
13. Epidemiology of irritable bowel syndrome in the United States
14. The incidence of clinically diagnosed irritable bowel syndrome in the community
15. Prevalence of gastrointestinal symptoms in the elderly: A population-based study
16. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases
17. A pilot study of motility and tone of the left colon in diarrhea due to functional disorders and dysautonomia
18. Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations
19. Risk factors for irritable bowel syndrome: Role of analgesics and fool sensitivities
20. Discrepancies between reported food intolerance and sensitization test findings in irritable bowel syndrome patients
21. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: A pilot study
22. Pain is temporally related to eating but not to defecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study
23. Medical costs in community subjects with irritable bowel syndrome
24. Functional digestive disorders (FDD) in the year 2000 - Economic impact
25. Economic burden of irritable bowel syndrome reappraised with strategies to control expenditures
26. Epidemiology of constipation (EPOC) study in the United States: Relation of clinical subtypes to sociodemographic features
27. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life
28. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom
29. Clinical economics review: Irritable bowel syndrome
30. Costs associated with healthcare resource use and productivity loss in patients with irritable bowel syndrome (IBS)
31. Irritable bowel syndrome. Diagnosis in the managed care era
32. Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome
33. Irritable bowel syndrome in office-based practice in the United States
34. Survey of the AGA membership relating to patients with functional gastrointestinal disorders
35. Motility disorders and stress: Significance to the irritable bowel syndrome
36. Alterations in man under stress. Experimental production of changes simulating the "irritable colon"
37. Postprandial colonic transit and motor activity in chronic constipation
38. Irritable bowel syndrome: Relationship of disorders in the transit of a single solid meal to symptom patterns
39. Transit through the proximal colon influences stool weight in the irritable bowel syndrome
40. Scintigraphic measurement of regional gut transit in idiopathic constipation
41. 3 antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome
42. Anorectal manometry in irritable bowel syndrome: Differences between diarrhoea and constipation predominant subjects
43. Colonic tone and motility in patients with irritable bowel syndrome
44. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
45. Ambulatory small intestinal motility in diarrhoea predominant irritable bowel syndrome
46. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome
47. Jejunal sensorimotor dysfunction in irritable bowel syndrome: Clinical and psychosocial features
48. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders
49. Scintigraphy of the whole gut: Clinical evaluation of transit disorders
50. Rapid gastric emptying in patients with functional diarrhea
51. Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome
52. Anorectal manometry in irritable bowel syndrome: Differences between diarrhoea and constipation predominant subjects
53. Altered rectal perception is a biological marker of patients with irritable bowel syndrome
54. Sigmoid afferent mechanisms in patients with irritable bowel syndrome
55. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients
56. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects
57. Evidence of a genetic contribution to functional bowel disorder
58. Predominant symptoms in irritable bowel correlate with specific autonomic nervous system abnormalities
59. Autonomic dysfunction in gastrointestinal motility disorders
60. The role of psychological and biological factors in postinfective gut dysfunction
61. Psychometric scores and persistence of irritable bowel after infectious diarrhea
62. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: Postal survey of patients
63. Bacterial toxins influence long-term bowel dysfunction following campylobacter enteritis
64. Mind over matter in the postinfective irritable bowel
65. Malabsorption of fructosesorbitol mixtures. Interactions causing abdominal distress
66. A comparison of symptoms after the consumption of milk or lactose-hydrolyzed milk by people with self-reported severe lactose intolerance
67. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome
68. A simple radiologic method to estimate the quantity of bowel gas
69. Food intolerance: A major factor in the pathogenesis of irritable bowel syndrome
70. Food intolerance and the irritable bowel syndrome
71. Abnormal colonic fermentation in irritable bowel syndrome
72. A secretory epithelium of the small intestine with increased sensitivity to bile acids in irritable bowel syndrome associated with diarrhoea
73. Intestinal gas dynamics and tolerance in humans
74. New insight on functional gut disease: Is gas handling the answer?
75. Stimulation of intestinal gas propulsion is the key to treat gas retention in functional patients
76. Ways in which emotion can affect the digestive tract. Helps in sizing up the patient
77. Can panic disorder present as irritable bowel syndrome?
78. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
79. Effects of stressful life events on bowel symptoms: Subjects with irritable bowel syndrome compared with subjects without bowel dysfunction
80. Psychiatric illness and the irritable bowel syndrome. Practical implications for the primary physician
81. Psychosocial factors in the irritable bowel syndrome: A multivariate study of patients and nonpatients with irritable bowel syndrome
82. Role of psychologic symptoms in irritable bowel syndrome: Comparison of community and clinic samples
83. Sexual and physical abuse and gastrointestinal illness
84. Gastrointestinal tract symptoms and self-reported abuse: A population-based study
85. Why should psychotherapy be a useful approach to management of patients with non-ulcer dyspepsia?
86. Controlled treatment trials in the irritable bowel syndrome: A critique
87. Symptoms of psychologic distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples
88. Diagnosing and treating patients with refractory functional gastrointestinal disorders
89. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
90. Prognosis in the irritable bowel syndrome: A 5-year prospective study
91. The irritable bowel syndrome: Long-term prognosis and the physician-patient interaction
92. Irritable bowel syndrome: The view from general practice
93. Does routine abdominal ultrasound enhance diagnostic accuracy in irritable bowel syndrome?
94. Is rectal biopsy necessary in irritable bowel syndrome?
95. Prevention of colorectal cancer: Guidelines based on new data
96. Colorectal cancer screening: Clinical guidelines and rationale
97. Screening guidelines for colorectal cancer
98. Clinical management of intractable constipation
99. Antidepressant therapy in 138 patients with irritable bowel syndrome: A five-year clinical experience
100. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome?
101. Comparison of diet composition in women with and without functional bowel disorder
102. Gastric wall tension determines perception of gastric distention
103. 2-adrenergic agents in humans
104. Pharmacological modulation of rectal tone alters perception of distention in humans
105. Effect of wheat bran on weight of stool and gastrointestinal transit time: A meta-analysis
106. Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome
107. The use of dietary fiber in the management of simple, childhood, idiopathic, recurrent abdominal pain: Results in a prospective, double-blind, randomized, controlled trial
108. The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind, cross-over study
109. Is bran efficacious in irritable bowel syndrome? A double-blind, placebo-controlled crossover study
110. Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: Correlation of symptom relief with whole gut transit time and stool weight
111. Bran supplementation in the treatment of irritable bowel syndrome
112. Bran and irritable bowel syndrome: Time for reappraisal
113. Tolerance for rectosigmoid distention in irritable bowel syndrome
114. Intestinal gas production from bacterial fermentation of undigested carbohydrate in irritable bowel syndrome
115. The role of intestinal gas in functional abdominal pain
116. Impaired ascending colon clearance in response to rapid small bowel transit in bloated irritable bowel syndrome: Bran exaggerates the problems
117. Clinical response to dietary fiber treatment of chronic constipation
118. Irritable bowel patients and their long-term response to a high fiber diet
119. Role of loperamide and placebo in management of irritable bowel syndrome
120. Effects of loperamide on anal sphincter function in patients complaining of chronic diarrhea with fecal incontinence and urgency
121. A double-blind, placebo-controlled trial with loperamide in irritable bowel syndrome
122. Loperamide treatment of the irritable bowel syndrome
123. Idiopathic bile salt catharsis
124. Idiopathic bile acid malabsorption: Long-term outcome
125. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhoea
126. 75Se HCAT test in the detection of bile acid malabsorption in functional diarrhoea and its correlation with small bowel transit
127. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
128. Antidepressants for functional gastrointestinal syndromes
129. Irritable colon and depression
130. Psychological significance of the irritable colon syndrome
131. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity
132. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans
133. The effect of trimipramine in patients with the irritable bowel syndrome
134. A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome
135. The effects of desipramine on IBS compared with atropine and placebo
136. Comparison of various treatments for irritable bowel syndrome
137. Fluoxetine
138. Hypnotherapy in irritable bowel syndrome
139. Psychotherapy in irritable bowel syndrome: A controlled outcome study
140. A controlled trial of psychological treatment for the irritable bowel syndrome
141. Hypnotherapy in the irritable bowel syndrome
142. Psychological treatments for irritable bowel syndrome: A critique of controlled treatment trials
143. Alternative medicine consultations and remedies in patients with irritable bowel syndrome
144. Irritable colon and ulcerative colitis. Alternative treatment is used frequently
145. Use of alternative medicine by patients attending a gastroenterology clinic
146. Why do patients seek a second opinion of alternative medicine?
147. Alternative therapy methods in functional disorders of the gastrointestinal system
148. Treatment of the irritable bowel syndrome with Chinese herbal medicine: A randomised controlled trial
149. 3-receptor antagonist
150. 3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat
151. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome
152. Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-IBS)
153. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome
154. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist
155. Efficacy and safety of alosetron in women with irritable bowel syndrome: A randomised, placebo-controlled trial
156. AIosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients
157. Efficacy of peripheral kappa agonist, fedotozine, vs. placebo in treatment of irritable bowel syndrome. A multicenter dose-response study
158. 4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
159. SDZ HTF 919 stimulates colonic motility and transit in vivo
160. 4 receptor partial agonist, on colorectal distension in rats
161. 4 receptor agonist
162. 4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome
163. 4 receptors mediate the R093877-induced changes in contractile patterns in the canine colon
164. Effect of a novel prokinetic drug, R093877, on gastrointestinal transit in healthy volunteers
165. 4 agonist, prucalopride, in healthy humans
166. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
167. Prucalopride improves bowel movement frequency and symptoms in patients with chronic constipation: Results of two double-blind, placebo-controlled trials
168. The efficacy and safety of prucalopride in patients with chronic constipation
169. Adrenergic modulation of human colonic motor and sensory function
170. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia: Effect on symptoms and gastric sensory and motor function
171. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man
172. Towards identifying optimal doses for alpha-2 adrenergic modulation of colonic and rectal motor and sensory function
173. Clonidine alters rectal motor and sensory function in irritable bowel syndrome
174. Stimulation of intestinal gas propulsion is the key to treat gas retention in functional patients
175. Serotonin: A mediator of brain-gut connection